PT - JOURNAL ARTICLE AU - Muecksch, Frauke AU - Wise, Helen AU - Templeton, Kate AU - Batchelor, Becky AU - Squires, Maria AU - McCance, Kirsty AU - Jarvis, Lisa AU - Malloy, Kristen AU - Furrie, Elizabeth AU - Richardson, Claire AU - MacGuire, Jacqueline AU - Godber, Ian AU - Burns, Alana AU - Mavin, Sally AU - Zhang, Fengwen AU - Schmidt, Fabian AU - Bieniasz, Paul AU - Jenks, Sara AU - Hatziioannou, Theodora TI - Longitudinal variation in SARS-CoV-2 antibody levels and emergence of viral variants: implications for the ability of serological assays to predict immunity AID - 10.1101/2021.07.02.21259939 DP - 2021 Jan 01 TA - medRxiv PG - 2021.07.02.21259939 4099 - http://medrxiv.org/content/early/2021/07/07/2021.07.02.21259939.short 4100 - http://medrxiv.org/content/early/2021/07/07/2021.07.02.21259939.full AB - Background Serological assays are being deployed to monitor antibody responses in SARS-CoV-2 convalescents and vaccine recipients. There is a need to determine whether such assays can predict immunity, as antibody levels wane and viral variants emerge.Methods We measured antibodies in a cohort of SARS-CoV-2 infected patients using several high-throughput serological tests and functional neutralization assays. The effects of time and spike protein sequence variation on the performance and predictive value of the various assays was assessed.Findings Neutralizing antibody titers decreased over the first few months post-infection but stabilized thereafter, at about 30% of the level observed shortly after infection. Serological assays commonly used to measure antibodies against SARS-CoV-2 displayed a range of sensitivities that declined to varying extents over time. Quantitative measurements generated by serological assays based on the spike protein were better at predicting neutralizing antibody titers than assays based on nucleocapsid, but performance was variable and manufacturer positivity thresholds were not able to predict the presence or absence of detectable neutralizing activity. Even though there was some deterioration in correlation between serological measurements and functional neutralization activity, some assays maintained an ability to predict neutralizing titers, even against variants of concern.Interpretation The ability of high throughput serological assays to predict neutralizing antibody titers is likely crucial for evaluation of immunity at the population scale. These data will facilitate the selection of the most suitable assays as surrogates of functional neutralizing activity and suggest that such measurements may have utility in clinical practice.Competing Interest StatementSJ & EF received honoraria from Siemens for an online webinar in October 2020 which was paid to their institutions. EF received sCOVG reagent from Siemens to support this study.Funding StatementFunding sources NIH (R01AI78788 to TH, R01 AI50111 to PDB) and NRS BioResource (SR1407 to SJ). The funders of the study had no role in the design, collection, analysis and interpretation of the data presented.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was obtained for this study to be carried out through the NHS Lothian BioResource (SR1407) and London-Brent Research Ethics Committee (REC ref: 20/HRA/3764 IRAS:28653). All recruits gave written and informed consent for serial blood sample collection. De-identified samples were shipped to the Rockefeller University whose IRB reviewed and approved the study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDe-identified data will be available for share following manuscript publication.